Literature DB >> 32062672

Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation.

Jack Y Ghannam1, Xin Xu2, Irina Maric3, Laura Dillon1, Yuesheng Li4, Matthew M Hsieh2, Christopher S Hourigan1, Courtney D Fitzhugh2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32062672      PMCID： PMC7118814          DOI： 10.1182/blood.2019004001

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  23 in total

1.  Malignancy in patients with sickle cell disease.

Authors:  William H Schultz; Russell E Ware
Journal:  Am J Hematol       Date:  2003-12       Impact factor: 10.047

2.  Sickle cell anemia terminating in acute myeloblastic leukemia.

Authors:  A G GOLDIN; K C KELTY; M F BEARD
Journal:  Ann Intern Med       Date:  1953-10       Impact factor: 25.391

3.  Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.

Authors:  Pedro Aurio Maia Filho; Jamilly Florêncio Pereira; Tarcísio Paulo de Almeida Filho; Bruno Coêlho Cavalcanti; Juliana Cordeiro de Sousa; Romélia Pinheiro Gonçalves Lemes
Journal:  Environ Mol Mutagen       Date:  2018-12-07       Impact factor: 3.216

4.  Sickle cell anemia with acute myeloid leukemia--(a case report).

Authors:  G C Samal
Journal:  Indian Pediatr       Date:  1979-05       Impact factor: 1.411

5.  Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT.

Authors:  Courtney D Fitzhugh; Matthew M Hsieh; Tiffani Taylor; Wynona Coles; Katherine Roskom; Delon Wilson; Elizabeth Wright; Neal Jeffries; Christopher J Gamper; Jonathan Powell; Leo Luznik; John F Tisdale
Journal:  Blood Adv       Date:  2017-04-19

6.  Bone-marrow transplantation in a patient with sickle-cell anemia.

Authors:  F L Johnson; A T Look; J Gockerman; M R Ruggiero; L Dalla-Pozza; F T Billings
Journal:  N Engl J Med       Date:  1984-09-20       Impact factor: 91.245

7.  Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia.

Authors:  James G Taylor; Deepika S Darbari; Deepika S Darari; Irina Maric; Zachariah McIver; Diane C Arthur
Journal:  Ann Intern Med       Date:  2011-11-15       Impact factor: 25.391

8.  Age-related clonal hematopoiesis associated with adverse outcomes.

Authors:  Siddhartha Jaiswal; Pierre Fontanillas; Jason Flannick; Alisa Manning; Peter V Grauman; Brenton G Mar; R Coleman Lindsley; Craig H Mermel; Noel Burtt; Alejandro Chavez; John M Higgins; Vladislav Moltchanov; Frank C Kuo; Michael J Kluk; Brian Henderson; Leena Kinnunen; Heikki A Koistinen; Claes Ladenvall; Gad Getz; Adolfo Correa; Benjamin F Banahan; Stacey Gabriel; Sekar Kathiresan; Heather M Stringham; Mark I McCarthy; Michael Boehnke; Jaakko Tuomilehto; Christopher Haiman; Leif Groop; Gil Atzmon; James G Wilson; Donna Neuberg; David Altshuler; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

9.  Hematologic malignancy in sickle cell disease: report of four cases and review of the literature.

Authors:  R B Stricker; C A Linker; T J Crowley; S H Embury
Journal:  Am J Hematol       Date:  1986-02       Impact factor: 10.047

10.  Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.

Authors:  Terrence N Wong; Giridharan Ramsingh; Andrew L Young; Christopher A Miller; Waseem Touma; John S Welch; Tamara L Lamprecht; Dong Shen; Jasreet Hundal; Robert S Fulton; Sharon Heath; Jack D Baty; Jeffery M Klco; Li Ding; Elaine R Mardis; Peter Westervelt; John F DiPersio; Matthew J Walter; Timothy A Graubert; Timothy J Ley; Todd Druley; Daniel C Link; Richard K Wilson
Journal:  Nature       Date:  2014-12-08       Impact factor: 49.962
View more
  17 in total

Review 1.  Evidence-Based Minireview: In young children with severe sickle cell disease, do the benefits of HLA-identical sibling donor HCT outweigh the risks?

Authors:  Niketa Shah; Lakshmanan Krishnamurti
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy.

Authors:  Tolulope O Rosanwo; Daniel E Bauer
Journal:  Mol Ther       Date:  2021-10-08       Impact factor: 11.454

3.  A pause in gene therapy: Reflecting on the unique challenges of sickle cell disease.

Authors:  Alexis Leonard; John F Tisdale
Journal:  Mol Ther       Date:  2021-03-19       Impact factor: 11.454

Review 4.  Genetic therapies for the first molecular disease.

Authors:  Phillip A Doerfler; Akshay Sharma; Jerlym S Porter; Yan Zheng; John F Tisdale; Mitchell J Weiss
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

5.  American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation.

Authors:  Julie Kanter; Robert I Liem; Françoise Bernaudin; Javier Bolaños-Meade; Courtney D Fitzhugh; Jane S Hankins; M Hassan Murad; Julie A Panepinto; Damiano Rondelli; Shalini Shenoy; John Wagner; Mark C Walters; Teonna Woolford; Joerg J Meerpohl; John Tisdale
Journal:  Blood Adv       Date:  2021-09-28

Review 6.  Understanding and overcoming adverse consequences of genome editing on hematopoietic stem and progenitor cells.

Authors:  Byung-Chul Lee; Richard J Lozano; Cynthia E Dunbar
Journal:  Mol Ther       Date:  2021-09-10       Impact factor: 11.454

Review 7.  Gene therapy for sickle cell disease: moving from the bench to the bedside.

Authors:  Allistair A Abraham; John F Tisdale
Journal:  Blood       Date:  2021-09-16       Impact factor: 25.476

8.  Clonal hematopoiesis in sickle cell disease.

Authors:  Thomas Pincez; Simon S K Lee; Yann Ilboudo; Michael Preuss; Anne-Laure Pham Hung d'Alexandry d'Orengiani; Pablo Bartolucci; Frédéric Galactéros; Philippe Joly; Daniel E Bauer; Ruth J F Loos; R Coleman Lindsley; Guillaume Lettre
Journal:  Blood       Date:  2021-11-25       Impact factor: 25.476

Review 9.  Research in Sickle Cell Disease: From Bedside to Bench to Bedside.

Authors:  Gabriel Salinas Cisneros; Swee Lay Thein
Journal:  Hemasphere       Date:  2021-06-01

10.  Murine bone marrow mesenchymal stromal cells have reduced hematopoietic maintenance ability in sickle cell disease.

Authors:  Alice Tang; Ana Nicolle Strat; Mahmudur Rahman; Helen Zhang; Weili Bao; Yunfeng Liu; David Shi; Xiuli An; Deepa Manwani; Patricia Shi; Karina Yazdanbakhsh; Avital Mendelson
Journal:  Blood       Date:  2021-12-16       Impact factor: 25.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.